Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
112 hedge funds and large institutions have $657M invested in Revance Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 53 increasing their positions, 14 reducing their positions, and 9 closing their positions.
279% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 14
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
21% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $939K
11% more funds holding
Funds holding: 101 → 112 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less capital invested
Capital invested by funds: $734M → $657M (-$76.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.8M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$19M |
| 3 |
BAMCO Inc
New York
|
+$8.83M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.32M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$7.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.25M |
| 2 |
Bank of New York Mellon
New York
|
-$4.33M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.42M |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$1.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.23M |
RVNC Hedge Fund Activity: Q1 2019 in Review
112 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2019, worth a combined $657M — down 10% from $734M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RVNC positions and 9 closed out — a net gain of 11 holders — while 53 added to existing stakes and 14 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $24.8M. The largest seller was Millennium Management, cutting an estimated $6.25M.
- 112 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2019, up from 101 in Q4 2018.
- Funds reported $657M of Revance Therapeutics, Inc. stock for Q1 2019, down 10% quarter-over-quarter.
- 20 funds opened new Revance Therapeutics, Inc. positions in Q1 2019 and 9 closed out, a net change of +11 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2019 was Wellington Management Group, an estimated $24.8M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2019 was Millennium Management, an estimated $6.25M sold.
Based on aggregated 13F filings for Q1 2019.